Anti-Human IgG Fc, AlpSdAbs® VHH(VcMMAF ×4)

Details and Advantages

Code: 023-101-102

Size: 100ug

Applications: Internalization Test

Specificity: Human IgG(Fcγ Fragment specific)

Conjugate: VcMMAF

Advantages:

High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production

Inquire Now

Next Product

Anti-Human IgG Fc, AlpSdAbs® VHH(VcMMAE ×4)

Product Description Manual MSDS FAQ Citations

Anti-Human IgG Fc, AlpSdAbs® VHH(VcMMAF ×4) is a monovalent, recombinant single-domain VHH antibody designed for studying the antibody internalization. This alpaca-derived VHH specifically targets the Fc region of human IgG and is conjugated to 4 molecules of VcMMAF (a potent microtubule inhibitor) at a site-specific position. It serves as a powerful tool for functional cytotoxicity-based internalization screening and evaluation of antibody potency prior to ADC development.

Based on immunoelectrophoresis and/or ELISA, it reacts specifically with the Fc fragment of human IgG heavy chain but not with the Fab portion. It enables direct assessment of internalization-dependent cytotoxicity in live cells, making it ideal for mechanistic studies, trafficking analysis, and high-throughput antibody screening.

Technical Specifications

Immunogen	Recombinant Fc region of human IgG
Host	Alpaca pacous
Isotype	VHH domain of alpaca IgG2b/2c
Conjugate	VcMMAF (2 moles VcMMAF per mole VHH)
Specificity	Human IgG (Fcγ fragment specific), including IgG1, IgG2, IgG3, IgG4 and their mutations (LALA or YTE)
Cross-Reactivity	Recognizes human IgG Fcγ fragment specifically, and reacts with cynomolgus IgG. No cross-reactivity with rabbit, mouse, rat, or goat IgG
Purity	Recombinant Expression and Affinity purified
Concentration	0.5 mg/ml
Formulation	Liquid, 10mM PBS (pH 7.4)
Storage	Store at –20 °C (Avoid freeze / thaw cycles)

Product Advantages

• VHH nano-secondary conjugated with potent cytotoxic payload VcMMAF (Two VHH Binding one IgG, DAR=4)
• Functional cytotoxicity-based internalization screening
• Evaluate internalization-dependent cytotoxicity in tumor cell models
• Rapidly compare internalization efficiency among multiple antibody candidates
• Support high-throughput screening for internalizing antibodies
• Ideal for rapid pre-selection of lead antibodies before formal ADC development
• High sensitivity with low background
• Compatible with multiple IgG subtypes (IgG1–IgG4 and common mutations)
• Simplified workflow for high-throughput assays

Discover more Nano Secondary Antibody-Drug Conjugates in this series.

Applications:

Antibody Internalization Test: 2 μg per 10 μg test antibody (molar ratio = 2:1)

Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.

Background

VHH are single-domain antibodies derived from the variable regions of the heavy chain of Camelidae immunoglobulin. The size of VHH is extremely small(<15KDa) compared to other forms of antibody fragments, which significantly increases the permeability of VHH. Thus, VHH is considered of great value for research, diagnostics, and therapeutics.

VcMMAF is a potent microtubule-disrupting toxin commonly used in antibody-drug conjugates (ADCs).

Ordering & Support

• Request COA or Quality Certificate for detailed batch information
• Contact Technical Support for dilution recommendations or application guidance

FAQ

Citations

Rapid In Vitro Cytotoxicity Testing Methods for Dual-Toxin ADCs --A new and efficient screening strategy for next-generation ADC development